AAPL   266.81 (-1.44%)
FB   202.54 (+0.74%)
MSFT   151.86 (+0.07%)
GOOGL   1,350.78 (+0.85%)
AMZN   1,756.98 (+0.31%)
CGC   21.05 (+12.87%)
NVDA   212.57 (+0.19%)
MU   46.71 (-2.57%)
BABA   201.35 (-0.27%)
GE   11.05 (-0.45%)
T   38.33 (+0.34%)
AMD   39.27 (-0.91%)
ACB   2.53 (+4.12%)
NFLX   308.05 (+0.23%)
BAC   33.57 (-0.30%)
GILD   67.05 (-0.04%)
DIS   147.05 (-0.41%)
AAPL   266.81 (-1.44%)
FB   202.54 (+0.74%)
MSFT   151.86 (+0.07%)
GOOGL   1,350.78 (+0.85%)
AMZN   1,756.98 (+0.31%)
CGC   21.05 (+12.87%)
NVDA   212.57 (+0.19%)
MU   46.71 (-2.57%)
BABA   201.35 (-0.27%)
GE   11.05 (-0.45%)
T   38.33 (+0.34%)
AMD   39.27 (-0.91%)
ACB   2.53 (+4.12%)
NFLX   308.05 (+0.23%)
BAC   33.57 (-0.30%)
GILD   67.05 (-0.04%)
DIS   147.05 (-0.41%)
AAPL   266.81 (-1.44%)
FB   202.54 (+0.74%)
MSFT   151.86 (+0.07%)
GOOGL   1,350.78 (+0.85%)
AMZN   1,756.98 (+0.31%)
CGC   21.05 (+12.87%)
NVDA   212.57 (+0.19%)
MU   46.71 (-2.57%)
BABA   201.35 (-0.27%)
GE   11.05 (-0.45%)
T   38.33 (+0.34%)
AMD   39.27 (-0.91%)
ACB   2.53 (+4.12%)
NFLX   308.05 (+0.23%)
BAC   33.57 (-0.30%)
GILD   67.05 (-0.04%)
DIS   147.05 (-0.41%)
AAPL   266.81 (-1.44%)
FB   202.54 (+0.74%)
MSFT   151.86 (+0.07%)
GOOGL   1,350.78 (+0.85%)
AMZN   1,756.98 (+0.31%)
CGC   21.05 (+12.87%)
NVDA   212.57 (+0.19%)
MU   46.71 (-2.57%)
BABA   201.35 (-0.27%)
GE   11.05 (-0.45%)
T   38.33 (+0.34%)
AMD   39.27 (-0.91%)
ACB   2.53 (+4.12%)
NFLX   308.05 (+0.23%)
BAC   33.57 (-0.30%)
GILD   67.05 (-0.04%)
DIS   147.05 (-0.41%)
Log in

NASDAQ:AUTL - Autolus Therapeutics Stock Price, Forecast & News

$15.84
+1.10 (+7.46 %)
(As of 12/9/2019 11:55 AM ET)
Today's Range
$15.00
Now: $15.84
$16.89
50-Day Range
$10.93
MA: $13.12
$16.27
52-Week Range
$9.50
Now: $15.84
$41.03
Volume95,913 shs
Average Volume108,143 shs
Market Capitalization$635.98 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUTL
CUSIPN/A
CIKN/A
Phone44-20-3829-6230

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.41 million

Profitability

Net Income$-12,860,000.00
Net Margins-3,576.93%

Miscellaneous

EmployeesN/A
Market Cap$635.98 million
Next Earnings Date2/24/2020 (Estimated)
OptionableNot Optionable

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.


Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics Ltd - (NASDAQ:AUTL) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.26. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $2 million. Autolus Therapeutics had a negative net margin of 3,576.93% and a negative return on equity of 39.54%. View Autolus Therapeutics' Earnings History.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Autolus Therapeutics.

What price target have analysts set for AUTL?

3 brokers have issued 12 month target prices for Autolus Therapeutics' shares. Their forecasts range from $24.00 to $26.00. On average, they anticipate Autolus Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 57.8% from the stock's current price. View Analyst Price Targets for Autolus Therapeutics.

What is the consensus analysts' recommendation for Autolus Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics.

What are Wall Street analysts saying about Autolus Therapeutics stock?

Here are some recent quotes from research analysts about Autolus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. " (11/12/2019)
  • 2. HC Wainwright analysts commented, "Our $24 price target, is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model, and reflects the recent dilution from the secondary offering. Our DCF is based on: beta of 1.50, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.4%, and tax rate of 15% beginning in FY 2028. Our rNPV for: (1) AUTO3 is $17; (2) AUTO1 is $4; and (3) AUTO4 is $3, which are derived from probability adjusted peak sales of: (1) $432M; (2) $150M; and (3) $96M, respectively." (9/12/2019)

Has Autolus Therapeutics been receiving favorable news coverage?

Media headlines about AUTL stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Autolus Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Autolus Therapeutics.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,340,000 shares, an increase of 7.2% from the October 31st total of 1,250,000 shares. Based on an average daily volume of 293,900 shares, the short-interest ratio is currently 4.6 days. Approximately 3.0% of the company's shares are short sold. View Autolus Therapeutics' Current Options Chain.

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the folowing people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 55)
  • Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)
  • Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)
  • Mr. Christopher Vann, Sr. VP & COO (Age 55)
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54)

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.48%), Granahan Investment Management Inc. MA (0.76%), Point72 Asset Management L.P. (0.19%), State Street Corp (0.03%) and Barclays PLC (0.01%).

Which major investors are buying Autolus Therapeutics stock?

AUTL stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Granahan Investment Management Inc. MA, State Street Corp and Barclays PLC.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $15.84.

How big of a company is Autolus Therapeutics?

Autolus Therapeutics has a market capitalization of $635.98 million and generates $1.41 million in revenue each year. The company earns $-12,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About Autolus Therapeutics.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is http://www.autolus.com/.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]


MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: What is Compound Interest?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel